Generate Biomedicines (NASDAQ:GENB) Shares Gap Up - Here's What Happened

Key Points

• Generate Biomedicines shares opened higher, rising from a previous close of $12.26 to $12.61 before trading around $12.51 on volume of roughly 796,000 shares.
• Analyst sentiment is broadly positive: six analysts rate the stock Buy, one Hold and one Sell, producing a “Moderate Buy” consensus and an average price target of $26.40.
• The company reported a quarterly loss of $0.52 per share, worse than the $0.48 consensus estimate, on $6.31 million in revenue; institutional investors also made several new investments in GENB.

Generate Biomedicines Inc (NASDAQ:GENB - Get Free Report)'s stock price gapped up before the market opened on Wednesday. The stock had previously closed at $12.26, but opened at $12.61. Generate Biomedicines shares last traded at $12.5120, with a volume of 796,486 shares traded.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on GENB. Wall Street Zen upgraded Generate Biomedicines from a "sell" rating to a "hold" rating in a report on Saturday, September 26th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Generate Biomedicines in a report on Monday, October 5th. Finally, Weiss Ratings upgraded Generate Biomedicines from a "sell (d)" rating to a "sell (d+)" rating in a research report on Friday, September 25th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $26.40.

Generate Biomedicines Stock Performance

The stock has a market capitalization of $1.59 billion and a PE ratio of -7.77. The company's fifty day simple moving average is $15.52 and its two-hundred day simple moving average is $14.43.

Generate Biomedicines (NASDAQ:GENB - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The business had revenue of $6.31 million for the quarter. Sell-side analysts forecast that Generate Biomedicines Inc will post -2.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of GENB. State Street Corp acquired a new stake in Generate Biomedicines during the 2nd quarter valued at $8,883,000. The Manufacturers Life Insurance Company acquired a new position in shares of Generate Biomedicines in the second quarter worth $1,431,000. Squarepoint Ops LLC acquired a new position in shares of Generate Biomedicines in the second quarter worth $530,000. AXQ Capital LP purchased a new stake in shares of Generate Biomedicines in the second quarter valued at $218,000. Finally, Braidwell LP purchased a new stake in shares of Generate Biomedicines in the second quarter valued at $55,398,000.

Generate Biomedicines Company Profile

Generate Biomedicines is a biotechnology company focused on discovering and developing protein-based medicines. The company uses generative artificial intelligence, machine learning and laboratory-based biological research to design new therapeutic proteins and identify candidates with potential applications in a range of diseases.

Its platform, often described as a generative biology approach, is designed to model biological systems and create proteins with desired characteristics rather than relying solely on modifying naturally occurring molecules.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.